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Continuous deep sedation in patients nearing death
Imprecise taxonomy makes interpreting trends difficult
Deep sedation is occasionally the only effective treat-
ment for refractory symptoms and suffering in termi-
nally ill patients. In their accompanying study, Rietjens 
and colleagues report a significant rise in continuous 
deep sedation in the Netherlands from 5.6% in 2001 to 
7.1% in 2005, while cases of euthanasia declined over 
the same period.1
Continuous deep sedation is an accepted treatment 
in the Netherlands for patients whose life expectancy 
is two weeks or less. The Dutch study reports that 1200 
fewer people died as a result of euthanasia but 1800 
more died as a result of terminal sedation in 2005 than 
in 2001. Although the increase follows the publica-
tion in 2002 of guidelines for general practitioners on 
the use of continuous deep sedation, and attention in 
the Dutch media, the cause of this trend is unclear. 
There is concern that continuous deep sedation may 
enable doctors to evade the procedural requirements 
for euthanasia. In the Dutch study, 9% of deaths during 
continuous sedation were preceded by a euthanasia 
request from the patient that was not granted,1 and last 
year 43% non-compliance with the Dutch prescribing 
guidelines for terminal sedation was reported.2
Few data are available on the frequency of these 
practices in the United States or United Kingdom 
because no comparable national population based 
studies have been carried out. However, sedation for 
the treatment of otherwise intractable symptoms has 
become accepted practice among US and UK clini-
cians treating patients with advanced incurable illnesses 
who are close to death. Controversy and resistance to 
the procedure have declined as concerns have been 
formally discussed, guidelines have been developed, 
and position statements of professional associations 
have been published.3 4
Because this treatment has become accepted in 
American hospice and palliative care practice, there is 
legitimate concern that sedation should not become a 
substitute for meticulous assessment and intensive treat-
ment of physical symptoms and psychological or spir-
itual distress. Specialist palliative care teams regularly 
help patients with previously intractable pain, delirium, 
anxiety, or dyspnoea become comfortable. Palliative 
care is personalised and costly, while sedation is a rela-
tively inexpensive, one size fits all treatment.
In 2007, international palliative care experts con-
cluded that sedation is a valid option when other treat-
ments fail to relieve symptoms in a patient expected 
to die within hours or days.5 The panel advocated 
small initial doses of a short acting benzodiazepine 
(midazolam), which are then titrated carefully against 
symptoms, allowing the patient to communicate inter-
mittently. The panel also recommended that advice 
from palliative care specialists should be sought before 
instituting sedation. Only 9% of Dutch general practi-
tioners in this study, which was completed before this 
recommendation was published, had done so.
The Dutch series is important in monitoring national 
trends and patterns of continuous deep sedation in one 
country. What lessons are applicable internationally? 
Meaningful interpretation of these findings is impeded 
not only by the legality and acceptance of euthanasia 
in the Netherlands, but more so by a persistent deficit 
of clearly defined taxonomy for component treatments 
and practices. The term “continuous deep sedation” 
is not precise enough to discern the reasoning and 
motives of clinicians needed to support relevant ethical 
analyses. Euthanasia implies the intention to hasten 
death. If the terms “palliative sedation” and its subcate-
gory, “terminal sedation,” are clearly defined they can 
contribute to a meaningful taxonomy.
“Palliative sedation” applies to treatment of pain or 
other physical distress with sedating drugs when other 
approaches have failed. In critical care units, palliative 
sedation may be used for a prolonged period until 
other treatments alleviate distress or the patient dete-
riorates, and it is used in other settings as short term 
crisis management. Although patients may die dur-
ing palliative sedation, it is not the intended treatment 
goal. “Terminal sedation” refers to palliative sedation 
prescribed for symptomatic patients who are expected 
to die soon. It is usually applied in situations in which 
life prolonging treatments have been stopped. Use of 
artificial hydration should be considered on its own 
merit in relation to symptom control. Death is the 
anticipated outcome, and titrated terminal sedation is 
given with the aim of ensuring that patients are com-
fortable as their disease causes death.
This Dutch study provides some insight into end of 
life management of patients with intractable suffering. 
We suggest that subsequent surveys that ask doctors 
about reported deaths use clear categories that can help 
us interpret empirical patterns of end of life care. Such 
surveys should also collect other pertinent information 
about treatment, such as concurrent use of medically 
administered nutrition and hydration, the drugs and 
doses given, and the interval between administration 
of sedating drugs and death. This would enhance our 
ability to compare trends related to these important 
components of end of life care from one country to 
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another over time. Further research must incorporate 
the perspectives of patients and families, as well as 
professionals from health care, spiritual care, social 
services and the social sciences, law, and ethics.
Clinicians and the societies they serve would ben-
efit from informed public discourse about ethical and 
effective ways to alleviate persistent suffering at the 
end of life.
Rietjens J, van Delden J, Onwuteaka-Philipsen B, Buiting H, van der 1 
Maas P, van der Heide A. Continuous deep sedation for patients nearing 
death in the Netherlands: descriptive study. BMJ 2008 doi: 10.1136/
bmj.39504.531505.25.
Hasselaar JG, Reuzel RP, Verhagen SC, de Graeff A, Vissers KC, Crul BJ. 2 
Improving prescription in palliative sedation: compliance with Dutch 
guidelines. Arch Intern Med 2007;167:1166-71.
Quill TE, Byock IR. Responding to intractable terminal suffering: the role of 3 
terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-
of-Life Care Consensus Panel. American College of Physicians-American 
Society of Internal Medicine. Ann Intern Med 2000;132:408-14.
Lo B, Rubenfeld G. Palliative sedation in dying patients: “we turn to it 4 
when everything else hasn’t worked.” JAMA 2005;294:1810-6.
De Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: 5 
a literature review and recommendations for standards. J Palliat Med 
2007;10:67-85.
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Is ventilation of the lungs necessary when starting car-
diopulmonary resuscitation (CPR) for out of hospital 
cardiac arrest? Increasing evidence shows that it has no 
effect on outcome and may even make matters worse. 
The American Heart Association has responded to this 
controversy by publishing a statement “Hands-only 
(compression-only) CPR: a call to action for bystander 
response to adults who experience out-of-hospital sudden 
cardiac arrest.”1 The main message of this statement is 
that by encouraging bystanders to provide at least chest 
compressions, the odds of survival from out of hospital 
cardiac arrest will be improved. 
Several animal studies show no survival benefit with 
the addition of ventilation during cardiopulmonary resus-
citation.1 A limitation of these studies, however, is that 
the airways of the animals are generally patent, which 
may enable chest compressions alone to generate some 
ventilation, particularly if gasping also occurs during 
chest compressions. Unconscious supine humans usu-
ally have an obstructed airway, and gasping occurs less 
often than in the animal models. In a recent Japanese 
study, only 7.1% of patients with out of hospital cardiac 
arrest were gasping when ambulance personnel arrived 
on the scene.2 Severe hypoxaemia developed rapidly in a 
compression-only cardiopulmonary resuscitation animal 
model with an obstructed airway.3
Surveys indicate that bystanders and medical profes-
sionals are reluctant to do mouth to mouth ventilation 
(rescue breathing), partly because of fears of infection, 
but also because it is considered unpleasant.4-6 Contrary 
to these findings, lay people trained in basic life support, 
who were interviewed after witnessing cardiac arrests 
but who did not perform bystander cardiopulmonary 
resuscitation, indicated that this was mainly because of 
panic; only four out of 279 (1.4%) of them said that it 
was because they objected to doing mouth to mouth 
ventilation.7 Compression-only cardiopulmonary resus-
citation is easier to learn than conventional resuscita-
tion.8 Lay people cannot follow telephone instructions 
from ambulance dispatchers to give mouth to mouth 
ventilation and chest compressions while waiting for 
an ambulance to arrive. In a study of dispatch assisted 
(telephone) cardiopulmonary resuscitation, instructions 
were more likely to be followed when the ventilation 
component was omitted, and survival was similar in the 
compression-only group.9
Several observational studies show similar survival 
rates when bystanders use compression-only cardiopul-
monary resuscitation or conventional resuscitation.1 Most 
importantly, all these studies show that any method of 
cardiopulmonary resuscitation increases survival com-
pared with no resuscitation. Although compression-only 
cardiopulmonary resuscitation is not associated with 
statistically better survival overall compared with con-
ventional cardiopulmonary resuscitation, one of these 
studies reported that outcome was significantly better for 
the compression-only group when response times were 
short.2 When the time from collapse to first attempt at 
resuscitation by a bystander was four minutes or less, a 
favourable neurological outcome was achieved in 10% 
(23/227) of the compression-only group compared with 
5% (18/351) of the conventional cardiopulmonary resus-
citation group (odds ratio 2.1, 95% confidence interval 
1.1 to 4.0). The most recent studies have been accompa-
nied by a plea for an urgent change in cardiopulmonary 
resuscitation guidelines.10
Should we teach lay people to perform compression-
only cardiopulmonary resuscitation? In the United King-
dom each year, bystander cardiopulmonary resuscitation 
occurs in a third of the roughly 30 000 ambulance treated 
cardiac arrests (figures based on unpublished Ambulance 
Service Association and Joint Royal Colleges Ambulance 
Liaison Committee data). The logic behind promoting 
compression-only cardiopulmonary resuscitation is that 
it increases the frequency of bystander cardiopulmonary 
resuscitation, and that any bystander cardiopulmonary 
resuscitation will increase the chance of long term sur-
vival compared with no resuscitation. This should benefit 
victims of out of hospital cardiac arrest from a cardiac 
cause when ambulance response times are short. Most 
(65-80%) out of hospital treated cardiac arrests have a 
primary cardiac cause.2 11 The potential losers of a com-
pression-only cardiopulmonary resuscitation approach 
are people who are likely to benefit from both ventilation 
and compressions, such as people having arrests that are 
associated with drowning, trauma, or airway obstruction; 
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those having primary respiratory arrest or prolonged car-
diac arrest; and children having cardiac arrests. People 
who favour compression-only resuscitation argue that 
these groups have a low survival rate even with con-
ventional cardiopulmonary resuscitation, and a change 
to compression-only cardiopulmonary resuscitation will 
have an overall benefit by increasing the number of sur-
vivors from primary cardiac arrest.
The American Heart Association statement indicates 
that compression-only cardiopulmonary resuscitation 
does not apply to unwitnessed cardiac arrest, cardiac 
arrest in children, or cardiac arrest presumed to have 
a non-cardiac cause. This implies that lay people must 
be able to differentiate a primary cardiac arrest from 
cardiac arrest from a non-cardiac cause and would need 
to be trained in conventional cardiopulmonary resusci-
tation as well as compression-only resuscitation. We do 
not know whether lay people can distinguish between 
primary cardiac arrest and primary respiratory arrest. If 
guidelines for lay people are changed to compression-
only cardiopulmonary resuscitation for witnessed sudden 
collapse, should we continue to teach mouth to mouth 
ventilation for primary respiratory arrest?
The evidence for and against the use of compres-
sion-only cardiopulmonary resuscitation instead of 
conventional resuscitation (30 compressions and two 
ventilations, repeated until help arrives) is being fully 
evaluated, along with a wide range of other resuscitation 
topics, in preparation for the 2010 Consensus Confer-
ence on Cardiopulmonary Resuscitation Science. After 
this conference, international resuscitation guidelines will 
be revised and implemented.
For the time being, in line with the current European 
and UK guidelines,12 lay rescuers who are not trained in 
cardiopulmonary resuscitation, or those not willing or una-
ble to give effective mouth to mouth ventilations, should 
give compression-only cardiopulmonary resuscitation at 
a rate of 100/minute. Those rescuers who are trained in 
conventional cardiopulmonary resuscitation should ensure 
that ventilations and any other interventions cause only 
minimal interruption of chest compressions.
Sayre MR, Berg RA, Cave DM, Page R, Potts J, White RD. Hands-only 1 
(compression-only) CPR: a call to action for bystander response to adults 
who experience out-of-hospital sudden cardiac arrest. Circulation 2008 
Mar 31 Epub ahead of print.
Cardiopulmonary resuscitation by bystanders with chest compression 2 
only (SOS-KANTO): an observational study. Lancet 2007;369:920-6.
Dorph E, Wik L, Stromme TA, Eriksen M, Steen PA. Oxygen delivery 3 
and return of spontaneous circulation with ventilation:compression 
ratio 2:30 versus chest compressions only CPR in pigs. Resuscitation 
2004;60:309-18.
Taniguchi T, Omi W, Inaba H. Attitudes toward the performance of 4 
bystander cardiopulmonary resuscitation in Japan. Resuscitation 
2007;75:82-7.
Hew P, Brenner B, Kaufman J. Reluctance of paramedics and emergency 5 
medical technicians to perform mouth-to-mouth resuscitation. J Emerg 
Med 1997;15:279-84.
Brenner BE, Kauffman J. Reluctance of internists and medical 6 
nurses to perform mouth-to-mouth resuscitation. Arch Intern Med 
1993;153:1763-9.
Swor R, Khan I, Domeier R, Honeycutt L, Chu K, Compton S. CPR training 7 
and CPR performance: do CPR-trained bystanders perform CPR? Acad 
Emerg Med 2006;13:596-601.
Heidenreich JW, Sanders AB, Higdon TA, Kern KB, Berg RA, Ewy GA. 8 
Uninterrupted chest compression CPR is easier to perform and 
remember than standard CPR. Resuscitation 2004;63:123-30.
Hallstrom A, Cobb L, Johnson E, Copass M. Cardiopulmonary 9 
resuscitation by chest compression alone or with mouth-to-mouth 
ventilation. N Engl J Med 2000;342:1546-53.
Ewy GA. Continuous-chest-compression cardiopulmonary resuscitation 10 
for cardiac arrest. Circulation 2007;116:2894-6.
Pell JP, Sirel JM, Marsden AK, Ford I, Walker NL, Cobbe SM. Presentation, 11 
management, and outcome of out of hospital cardiopulmonary arrest: 
comparison by underlying aetiology. Heart 2003;8:839-42.
Handley AJ, Koster RW, Monsieurs K, Perkins GD, Davies S, Bossaert 12 
L. European Resuscitation Council Guidelines for Resuscitation 2005. 
Section 2: adult basic life support and use of automated external 
defibrillators. Resuscitation 2005;67(suppl 1):S7-24.
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Non-invasive detection of fetal RHD status using mater-
nal plasma is one of the few real advances in fetal medi-
cine or obstetrics in recent years. DNA amplification of 
one or more region of the RHD gene can predict the fetal 
genotype with an accuracy of almost 99%.1 2 This means 
that invasive procedures (amniocentesis and chorionic 
villus sampling)—which carry a small but important risk 
of pregnancy loss and may also increase the risk of sen-
sitisation in pregnancies at risk from fetal haemolytic 
disease—can be abandoned.
Non-invasive ascertainment of the fetal RHD geno-
type (and other red cell antigens) is now used routinely 
in the United Kingdom and elsewhere in the world.3 
The technology, although labour intensive, is relatively 
simple and very reliable. In the accompanying study, 
Finning and colleagues assess the feasibility of applying 
a high throughput method for predicting RhD pheno-
type from fetal DNA in the plasma of pregnant women 
who are RhD negative.4
The incidence of RHD alloimmunisation has fallen 
greatly since the introduction of anti-RhD prophylaxis. 
In the 1960s prophylaxis was given in the postpartum 
period, and more recently after sensitising events and 
during the antenatal period. Antenatal prophylaxis is 
now offered to all RHD negative women in the UK and 
most developed countries regardless of the fetal geno-
type. But this approach has problems. Anti-D immuno-
globulin is produced from pooled plasma taken from 
RHD negative male donors who have been injected with 
RhD positive red cells. Although the plasma is purified, 
the risk of infection remains. Outbreaks of hepatitis C 
have occurred, but with modern techniques the risk is 
minimal, although the possibility of infection with a viral 
or prion agent remains. Anti-RhD immunoglobulin is 
also in short supply and expensive, and the logistics of 
giving one or two doses antenatally is labour intensive 
and expensive. These injections are also painful and 
inconvenient, and many mothers have difficulty in 
accepting their need, especially as they are given without 
regard for fetal RHD status.
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Oral bisphosphonates and atrial fibrillation
The risk is negligible, and does not offset the benefits of reducing fractures
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The benefits of bisphosphonates for the prevention 
of fracture in patients with osteoporosis are not dis-
puted,1 2 and one trial has also reported reduced mor-
tality in these patients.3 Nevertheless, bisphosphonates 
are underused by those most likely to benefit—elderly 
patients with fractures.2 This shortfall in care was dif-
ficult to rectify even while bisphosphonates were con-
sidered effective and safe,2 but matters will probably 
get worse after recent reports that these drugs might 
increase the risk of atrial fibrillation.3-6 Even fewer eli-
gible patients are now likely to start taking bisphospho-
nates, and more treated patients are likely to stop taking 
them. This would be justified if the risk of atrial fibril-
lation were real and large enough to offset the known 
benefits for fracture reduction. However, this poten-
tially increased risk is challenged by an accompanying 
population based observational study by Sørensen and 
colleagues, which finds no significant increase in atrial 
fibrillation or flutter in women taking bisphosphonates 
for osteoporosis.7
It was only a matter of time before osteoporosis, its 
treatments, and cardiovascular events were linked.8 9 
Osteoporosis is common, it affects people with an 
increased risk of cardiovascular disease—such as post-
menopausal women and elderly people—and it has 
been associated with adverse cardiovascular events.9 
Currently, non-invasive fetal RHD genotyping is 
usually available only to women who have been sen-
sitised—indicated by the detection of anti-D antibodies 
in an antenatal sample. After confirmation of the fetal 
genotype, only women carrying an RHD positive fetus 
are monitored for signs of fetal anaemia. Women with 
an RHD negative fetus can be discharged to routine 
obstetric care.
In their prospective study, Finning and colleagues 
assess high throughput RHD genotyping of fetal DNA 
in maternal plasma at 28 weeks—just before the first 
dose of antenatal anti-D injection—in about 1800 RHD 
 negative women. The correct fetal genotype was pre-
dicted in almost 96% of cases, with a small false negative 
rate of 0.16%. The results were either inconclusive or 
unobtainable in only 3.4% of cases. These findings are 
important for two reasons. Firstly, they demonstrate the 
reliability of the automated technique and the feasibility 
of large scale antenatal testing. Secondly, if this approach 
was used for all RHD negative women, only 2% of these 
women would receive unnecessary anti-D prophylaxis, 
compared with 38% using the current system. This is a 
substantial reduction of an antenatal intervention.
The benefits of wider implementation of antenatal fetal 
genotyping are obvious. Antenatal prophylaxis can be 
given to those women who actually need it. The need 
for anti-RhD prophylaxis after potential sensitising events 
can also be eliminated if the fetus is definitely not at risk. 
This approach may also have financial implications. 
Although Finning and colleagues’ study did not assess 
costs, mass testing would probably reduce costs. The 
costs of testing everyone need to be balanced against the 
costs of giving immunoglobulin to everyone, but again 
mass testing is likely to result in a net saving by reducing 
pharmacy and manpower costs.
The consequences of a false negative result are impor-
tant because withholding prophylaxis could potentially 
result in alloimmunisation and put the fetus and subse-
quent pregnancies at risk of haemolytic disease. In this 
study, only three samples (0.16%) gave false negative 
results. However, these samples were analysed more 
than 14 days from collection because of problems with 
transport. This delay would reduce the accuracy of the 
results because the amount of maternal DNA relative 
to fetal DNA increases in older samples, probably as 
a result of lysis of maternal cells in the specimen. The 
authors point out that under normal laboratory testing 
criteria these samples would have been discarded.
The consequences of a false positive result are far 
less detrimental. Some women will receive unnecessary 
anti-RhD prophylaxis as they do now, but the num-
bers would be small. Strict adherence to protocol would 
minimise the risks of false negative, false positive, or 
inconclusive results.
Although this study looked at samples taken from 
women at 28 weeks’ gestation, many potentially sensi-
tising events occur before this time. If fetal genotyping 
is performed only in the third trimester many women 
will still receive unnecessary anti-RhD prophylaxis. Fur-
thermore, prophylaxis after invasive first or early second 
trimester procedures will still be required. The goal of 
non-invasive testing is to determine fetal genotype as 
early in pregnancy as possible. Earlier gestation feasibil-
ity studies are in progress.
Universal fetal genotyping of all RHD negative women 
is the logical extension of a service that is already readily 
available. Automated techniques should make mass test-
ing easier and cost effective, and they should minimise 
the risks of receiving an unnecessary blood product. If 
these techniques are shown to be as reliable earlier in 
pregnancy the arguments for recommending universal 
testing will be compelling.
Minon JM, Gerard C, Senterre JM, Schaaps JP, Foidart JM. Routine fetal 1 
RHD genotyping with maternal plasma: a four-year experience in 
Belgium. Transfusion 2008;48:373-81. 
Rouillac-Le Sciellour C, Puillandre P, Gillot R, Baulard C, Métral S, Le Van 2 
Kim C, et al. Large-scale pre-diagnosis study of fetal RHD genotyping by 
PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn 
2004;8:23-31.
Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K 3 
(Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal 
plasma. Transfusion 2007;47:2126-33.
Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Effect of 4 
high throughput RHD typing of fetal DNA in maternal plasma on use of 
anti-RhD immunoglobulin in RhD negative pregnant women: prospective 
trial. BMJ 2008; doi: 10.1136/bmj.39518.463206.25.
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Classic risk factors for atrial fibrillation such as older 
age, hyperthyroidism, and smoking increase the risk of 
osteoporosis. Also, both osteoporosis and atrial fibrilla-
tion can be relatively clinically silent. For example, 
implantable event monitor studies of patients with 
treated atrial fibrillation find almost 40% of those with 
extended (>48 hours) recurrences are completely 
asymptomatic.10 With this scenario of at risk patients 
sharing similar risk factors, any secondary or post hoc 
analyses of osteoporosis treatments and adverse cardio-
vascular events will be difficult to interpret and suscep-
tible to serious confounding and problems related to 
multiple comparisons.8
So how strong is the evidence that bisphosphonates 
cause atrial fibrillation? To date, four studies have 
reported the link between these drugs and atrial fibril-
lation (see table on bmj.com).3-6 Of most concern is the 
horizon pivotal fracture trial,3 which compared annual 
intravenous zoledronic acid with placebo in almost 
7800 postmenopausal women. Over three years, new 
atrial fibrillation did not significantly increase (2.4% of 
zoledronic acid users v 1.9% of controls; P=0.12); how-
ever, the ill defined entity of “serious” atrial fibrillation 
did significantly increase (1.3% of zoledronic acid users v 
0.5% of controls; P<0.001). The evidence available so far 
indicates that the absolute risk of atrial fibrillation is very 
small, and if present at all, it is probably associated with 
intravenous zoledronic acid and not the more commonly 
used oral agents (see table on bmj.com). A meta-analysis 
of individual patient data might help to define the risk of 
atrial fibrillation with bisphosphonates.
That said, secondary analyses from trials and 
 meta-analyses may not constitute best evidence when 
dealing with rare drug related adverse event rates (<1-2%) 
and two common conditions that are found in the same 
older population. Unlike the use of non-randomised stud-
ies to estimate treatment effects without a trial (as used for 
oestrogen and heart attack) or to find wholly unexpected 
benefits (as used for statins and prevention of sepsis or 
cancer), a large and well conducted observational study 
is perhaps better suited to determining unexpected harm 
from commonly used drugs.11
Sørenson and colleagues report such a study.7 They 
investigated disodium etidronate and alendronate in 
a Danish population based nested case-control study 
(around 14 000 cases of atrial fibrillation and around 
68 000 controls) conducted from 1999 to 2005. The 
timing of their study is important because prescribers 
would have had no concerns about any risk of atrial 
fibrillation, which otherwise might have introduced 
confounding by prognosis.11 In terms of databases and 
methods used, the study is rigorous and adequately 
powered. The investigators report almost no difference 
in the use of bisphosphonates in people with atrial 
fibrillation and those without (3.2% of current users 
had atrial fibrillation v 2.9% of non-users). No associa-
tion was seen in appropriately adjusted analyses that 
examined new users versus not new users (the least 
biased comparison), former users versus not former 
users, and long duration versus short duration of use. 
To replicate “serious atrial fibrillation” as reported in 
trials (see table on bmj.com), Sørenson and colleagues 
also restricted analyses to events needing hospital 
admission or  cardioversion, and again they found no 
clinically important associations.
The main limitation of their work is lack of  information 
about zoledronic acid. This is important. Previous 
reports5 6 and Sørenson and colleagues’ work7 sug-
gest that oral bisphosphonates are safe with respect to 
atrial fibrillation. But atrial fibrillation might possibly 
be triggered soon after an infusion with zoledronic acid 
(or other intravenous bisphosphonates) as a result of 
the release of proinflammatory cytokines or transient 
 hypocalcaemia and secondary hyperparathyroidism.5 7 
However, in the HORIZON pivotal fracture trial, most 
cases of atrial fibrillation occurred months after infusion, 
and  electrocardiograms done in 559 patients before 
and nine to 11 days after infusion did not differ with 
respect to the presence of arrhythmias, which suggests 
that neither of these possible mechanisms was responsi-
ble.3 Nevertheless, the makers of zoledronic acid should 
do their utmost to confirm or allay concern, by pooling 
individual patient data and conducting postmarketing 
surveillance studies.
What are the implications for clinicians who com-
monly and appropriately prescribe oral bisphos-
phonates for their older patients with fractures and 
osteoporosis? For now, beyond taking the patient’s 
pulse and ordering an electrocardiogram when it is 
irregular,12 available evidence suggests that business 
should carry on as usual—the risk of atrial fibrillation 
associated with oral  bisphosphonates seems to be van-
ishingly small if it exists at all, and it is unlikely to 
ever offset the confirmed benefits of these drugs in the 
prevention of fractures.
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selecting medical students
Tests of cognitive ability are probably the best method at present
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The selection of the doctors of tomorrow is a subject 
of constant interest because it raises questions about 
ensuring equity, predicting human behaviour, and 
defining the characteristics of a good doctor. In the 
United Kingdom, it costs about £200 000 (€260 000; 
$400 000) to train each medical student, but the cost of 
getting the selection wrong is much greater.
Selection takes place under considerable time pres-
sure—in the UK around 19 000 applicants must be 
screened for some 8000 places in less than six months, 
and each applicant may apply to four medical schools. 
The selection ratio in the United States is remarkably 
similar—around 42% of 42 000 applicants were success-
ful in 2007, although each student made an average of 
13 applications. 
Different specialties have different requirements, but 
from our reading of the literature we distil three broad 
attributes that doctors should have—cognitive ability 
(including linguistic and mathematical intelligence, 
 problem solving capacity and memory); humanity (kind-
ness, empathy, emotional intelligence, bedside manner 
and ability to work in a team); and diligence (care in clin-
ical practice, capacity to work hard, punctuality, honesty 
and conscientiousness). Although the best option would 
be to screen potential doctors for all these attributes, 
the evidence suggests that only cognitive ability can be 
assessed with reasonable accuracy by a mass selection 
process. School examination results have been shown 
to predict academic performance at medical school.1 
However, it has been argued that British A levels are 
not useful because most candidates applying for medical 
school achieve the top grades and also not fair because 
they favour students from more privileged backgrounds. 
These criticisms could be rectified by basing selection on 
actual marks awarded rather than course grades on an 
A-E scale and adjusting entry requirements according to 
the applicant’s background.
Despite these potential solutions, some medical 
schools have introduced aptitude tests, based mainly 
on cognitive tasks. Some tests, such as the biomedical 
admissions test, correlate well with preclinical exami-
nation results,2 whereas others, such as the graduate 
Australian medical school admissions test, are less pre-
dictive.3 These aptitude tests do not seem to predict 
clinical performance,3 4 so they may have little value as 
independent predictors of performance beyond medi-
cal school. Furthermore, aptitude tests are costly for 
candidates and universities and do not seem to improve 
prediction over public examination marks alone.
Can psychological tests be used in selection? Personal-
ity influences career progression and job satisfaction; doc-
tors who score highly for introversion and neuroticism 
make relatively heavy weather of their professional lives.5 
These same traits, however, may also predispose doctors 
towards safe and careful clinical behaviour.6 We simply 
do not know the mixture of traits that is most predictive 
of both diligent service and personal progression.
Tests to measure “empathy” are not useful for selec-
tion because the results vary over time and such tests 
are poor predictors of clinical performance.7 In addi-
tion, unlike IQ scores or examination results, psycho-
logical tests can be manipulated to provide socially 
desirable answers. Questions designed to spot “fak-
ing” are far from foolproof,8 and it would be unfair to 
exclude students on the basis of alleged gaming.
In the meantime, we are left with another relatively 
unstudied process: the short medical student inter-
view. Interviews promise much and can be an effec-
tive recruitment tool, but their predictive accuracy is 
low.9 Agreement among interviewers is slightly greater 
at the extremes of the rating scale, so interviews could 
help eliminate extreme phenotypes.10 Even in these 
cases, however, interviews let through people they are 
meant to eliminate,11 and they may be biased towards 
people with a pleasing appearance. Interviews have 
been described as “a very elaborate, labour intensive 
and expensive lottery,”12 and we recommend that they 
are used only in the context of research, to test whether 
improvements to the interview process can predict a 
desirable behaviour downstream.
As interviews and psychological tests seem unable 
to select for desired attributes, we think that tests of 
cognitive ability are the best option for the present. We 
favour examination percentage scores over IQ scores 
or aptitude tests because the cognitive processes they 
test are similar to those used in clinical practice—the 
application of knowledge to a problem.
Clever people are not known to be systematically 
less humane than others.12 So, in selecting students 
we might as well test for the one attribute for which 
valid methods of prediction exist—cognitive ability—
while using the opportunity to “test the test” and add 
to the currently sparse evidence base.4 For example, 
the proposed pilot schemes for specialty selection in 
the English Modernising Medical Careers programme 
will be evaluated prospectively. Many countries in 
continental Europe use random selection, with each 
student’s chances weighted by school leaving examina-
tion results. While we would rather rely on examination 
marks alone, such a “weighted lottery” at least avoids 
the illusion of scientific probity inherent in psychologi-
cal tests or interviews. 
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